Are you Dr. Deyle?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 27 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
200 1st St Sw
Rochester, MN 55905Phone+1 507-284-2511
Summary
- Dr. David Deyle, MD is a board certified medical geneticist in Rochester, Minnesota. He is currently licensed to practice medicine in Minnesota, Arizona, and Florida. He is affiliated with Mayo Clinic Hospital - Rochester and is an Assistant Professor at Mayo Medical School.
Education & Training
- University of WashingtonResidency, Medical Genetics and Genomics, 2004 - 2006
- University of MinnesotaResidency, Internal Medicine/Pediatrics, 2000 - 2004
- University of Minnesota Medical SchoolClass of 2000
Certifications & Licensure
- MN State Medical License 2012 - 2025
- AZ State Medical License 2016 - 2022
- FL State Medical License 2016 - 2020
- WA State Medical License 2004 - 2013
- American Board of Medical Genetics and Genomics Clinical Genetics and Genomics
Publications & Presentations
PubMed
- Semiautomated approach focused on new genomic information results in time and effort-efficient reannotation of negative exome data.Alejandro Ferrer, Patrick Duffy, Rory J Olson, Michael A Meiners, Laura Schultz-Rogers
Human Genetics. 2024-05-01 - 7 citationsVosoritide Therapy in Children with Achondroplasia: Early Experience and Practical Considerations for Clinical Practice.Oliver Semler, Valérie Cormier-Daire, Ekkehart Lausch, Michael B Bober, Ricki Carroll
Advances in Therapy. 2024-01-01 - 1 citationsThoracic Aortic Aneurysmal Disease: Comprehensive Recommendations for the Primary Care Physician.Prajwal Reddy, Kaavya S Nair, Vinayak Kumar, Juan M Bowen, David R Deyle
Mayo Clinic Proceedings. 2024-01-01
Press Mentions
- Castle Creek Biosciences Expands Its Innovative Gene Therapy Platform for Rare Genetic Connective Tissue Disorders Through Research Collaboration with Mayo ClinicSeptember 29th, 2021
- Research Grants Aim to Advance Regenerative Medicine Toward the PracticeJune 29th, 2020
- Recombinetics Announces Collaboration with Mayo Clinic to Develop the First-Ever Swine Models of Osteogenesis ImperfectaOctober 7th, 2019
- Join now to see all
Grant Support
- Gene Targeting With AAV Vectors For The Treatment Of Osteogenesis ImperfectaNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2008–2011